Kiran de Jesus
Physician Assistant · New York, NYNPI 1023663622
Payments from drug & device makers
Across 285 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- UCB, Inc.$658
- AbbVie$637
- Johnson & Johnson$494
- AstraZeneca$362
- Pfizer$323
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,14398%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 63 | $1,159 |
| UCB, Inc. | 42 | $658 |
| AbbVie | 38 | $637 |
| Johnson & Johnson(2 entities) | 19 | $494 |
| AstraZeneca | 12 | $362 |
| Pfizer | 35 | $323 |
| Novartis | 17 | $311 |
| GSK | 12 | $291 |
| Mallinckrodt Hospital Products Inc. | 8 | $180 |
| Organon | 8 | $140 |
| Radius Health, Inc. | 6 | $138 |
| Aurinia Pharma U.S., Inc. | 5 | $106 |
| Lilly USA, LLC | 5 | $105 |
| Sandoz | 3 | $82 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Boehringer Ingelheim | 2 | $40 |
| Sobi, Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,242 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $296,043 |
| RinvoqUpadacitinib | 11 | $71,212 |
| Leflunomide | 40 | $3,125 |
| Celecoxib | 78 | $2,862 |
| Hydroxychloroquine Sulfate | 54 | $2,676 |
| MethotrexateMethotrexate Sodium | 110 | $2,086 |
| Gabapentin | 52 | $929 |
| Duloxetine Hcl | 15 | $466 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 18 | $324 |
| Sulfasalazine DrSulfasalazine | 14 | $292 |
| Sulfasalazine | 13 | $262 |
| Alendronate Sodium | 33 | $244 |
| Folic Acid | 29 | $203 |
| Meloxicam | 20 | $121 |
| Prednisone | 19 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $637 | $71,21211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in New York
- Kristyl Cuenca-SiskoNew York$478K
- Cameron KiserNew York$225K
- Mervat FalahNew York$143K
- Marlene TaylorNew York$109K
- Natalie TafelNew York$77K
- Edwin CalderonNew York$59K
- Jonathan YehNew York$57K
- Emily ElbogenNew York$49K
- Jaclyn ChurchillNew York$48K
- Russell BrandweinNew York$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.